We would like to provide a clarification to the reader about our article ' In Italy tocilizumab adheres to the payback system, so its ex-factory price does not include the ex-ante discount of 5%, differently from adalimumab and etanercept. The detail of the ex-post economic compensation for tocilizumab is not publicly available so we could not take it into account. Therefore, for all the drugs considered in the analysis, for comparability purpose only the temporary discount of -5% imposed by national law is taken into consideration. authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.
Disclosures. Alberto Batticciotto, Roberto Ravasio, Marta Riva, and Piercarlo Sarzi-Puttini declare that they have no conflicts of interest in the research.
Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
